» Articles » PMID: 36257142

Intranasal Administration of Mitochondria Alleviated Cognitive Impairments and Mitochondrial Dysfunction in the Photothrombotic Model of MPFC Stroke in Mice

Overview
Date 2022 Oct 18
PMID 36257142
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Dysfunction in mitochondrial activity may have profound role in ischemic stroke-induced neuronal death, hence maintaining the mitochondrial function seems to be valuable for neuronal viability and neurological improvement.

Methods: C57BL/6J mice were allocated into sham and stroke groups. Mice in the stroke groups underwent photothrombosis-induced stroke in the medial prefrontal cortex (mPFC) and were divided into the following subgroups; RB, Mito 85, Mito 170, and Mito 340, and received their respective treatments via intra-nasal route every other day (3 days per week) for one week. A battery of behavioral tests including social interaction, passive avoidance, and the Lashley III maze was used to investigate social, contextual, and spatial memories. Moreover, changes in mitochondrial function, including reactive oxygen species (ROS) and ATP levels, and mitochondrial membrane potential, were assessed in mPFC. The expression of growth-associated protein 43 (GAP-43), post-synaptic density-95 (PSD-95), and synaptophysin (SYP) was detected by western blotting.

Results: Behavioral results revealed that mitotherapy alleviated ischemia-induced memory impairment. Also, transplantation of exogenous mitochondria lowered ROS, restored ATP generation, and improved mitochondrial membrane potential. Induction of ischemia decreased the levels of synaptic markers in mPFC while exogenous mitochondria (170 and 340µg) significantly upregulated the expression of GAP-43 and PSD-95 after ischemic stroke.

Conclusion: Our research highlighted the importance of mitotherapy in regulating synaptic markers expression and mitochondria function, which could represent a potential strategy for improving cognitive and memory deficits following stroke.

Citing Articles

Molecular and cellular mechanisms of mitochondria transfer in models of central nervous system disease.

Nakano T, Irie K, Matsuo K, Mishima K, Nakamura Y J Cereb Blood Flow Metab. 2024; :271678X241300223.

PMID: 39539186 PMC: 11565516. DOI: 10.1177/0271678X241300223.


Acute Administration of Edaravone Improves Cognitive Impairment in a Mouse Model of mPFC Ischemia: Crosstalk Between Necroptosis, Neuroinflammation, and Antioxidant Defense.

Barati A, Moghimi S, Taghavi Zanjani K, Rohani M, Sohrabi Hesar M, Arfaie A Mol Neurobiol. 2024; 62(4):4420-4434.

PMID: 39448519 DOI: 10.1007/s12035-024-04541-6.


Mitochondrion-based organellar therapies for central nervous system diseases.

Zhao M, Wang J, Zhu S, Wang M, Chen C, Wang L Cell Commun Signal. 2024; 22(1):487.

PMID: 39390521 PMC: 11468137. DOI: 10.1186/s12964-024-01843-z.


Nasal administration of mitochondria relieves depressive- and anxiety-like behaviors in male mice exposed to restraint stress through the suppression ROS/NLRP3/caspase-1/IL-1β signaling pathway.

Mafikandi V, Seyedaghamiri F, Hosseinzadeh N, Shahabi P, Shafiee-Kandjani A, Babaie S Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39333279 DOI: 10.1007/s00210-024-03487-9.


Klotho: molecular mechanisms and emerging therapeutics in central nervous system diseases.

Hosseini L, Babaie S, Shahabi P, Fekri K, Shafiee-Kandjani A, Mafikandi V Mol Biol Rep. 2024; 51(1):913.

PMID: 39153108 DOI: 10.1007/s11033-024-09862-2.